SFM
VKTX icon

Sphera Funds Management’s Viking Therapeutics VKTX Stock Holding History

Sphera Funds Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-23,900
Closed -$416K – 126
2018
Q3 		$416K Buy
+23,900
New +$284K 0.05% 101

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Sphera Funds Management's VKTX Position: Q2 2025 in Review

Sphera Funds Management sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 83,270 shares — an estimated $2.01M sold.

Sphera Funds Management first reported a position in VKTX in Q3 2017 and held it in 12 quarters. The position peaked at $15M in Q3 2018. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

  • Sphera Funds Management reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sphera Funds Management sold 83,270 Viking Therapeutics shares in Q2 2025, an estimated $2.01M.
  • Sphera Funds Management first reported a position in Viking Therapeutics in Q3 2017 and held it in 12 quarters.
  • Sphera Funds Management's Viking Therapeutics position peaked at $15M in Q3 2018.
  • 391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.